- Direction
- Inflecting
- Own history
- —
- Peers
- 63th
- Persistence
- REVERSING
· Pharmaceutical Preparations
RESEARCH SNAPSHOTVanda Pharmaceuticals Inc.'s latest supported as-filed period reports revenue of $69.8M. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
Separate current dimensions—not a universal score or investment ranking.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.capex_revenue_ratio
Raw value 0.45% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -40.73% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value 24.10% · CORE
Level · gp.fundamentals.inventory_revenue_ratio
Raw value 2.19% · OPTIONAL
Level · gp.fundamentals.operating_margin
Raw value -33.69% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 39.56% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 2 independently calculated changes: Cash & equivalents decreased 31.0%; Operating cash flow decreased 103.7%.
2 evidence-backed componentsThis cluster groups 3 independently calculated changes: Revenue increased 24.1%; Operating margin moved 2192 bp higher; Operating income increased 24.8%.
3 evidence-backed componentsThis cluster groups 2 independently calculated changes: Shares outstanding increased 2.3%; SBC / revenue moved 17 bp higher.
2 evidence-backed componentsThis cluster groups 2 independently calculated changes: Capital expenditure increased 93.2%; Capex / revenue moved 16 bp higher.
2 evidence-backed componentsCurrent assets changed -33.0% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
VNDA · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001347178-26-000002SEC ↗8-KOct 28, 2026Period Oct 28, 20260001628280-26-067886SEC ↗10-QAug 6, 2026Period Jun 30, 20260001628280-26-053855SEC ↗8-KAug 5, 2026Period Aug 5, 20260001628280-26-053308SEC ↗4Jun 8, 2026Period Jun 4, 20260001193125-26-261871SEC ↗4Jun 8, 2026Period Jun 4, 20260001193125-26-261811SEC ↗4Jun 8, 2026Period Jun 4, 20260001193125-26-261806SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Jun 4, 2026Filed Jun 8, 2026 | McGuire Daniel PatrickSVP, GC and Secretary | Grant Or AwardDirect | 80,000 | $0 | $0 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Raw value 3.35% · OPTIONAL
Current assets changed -35.1% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Total assets changed -34.0% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Total assets changed -36.4% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Working capital changed -63.3% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Working capital changed -66.6% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Current ratio changed -50.4% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-09-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001193125-26-261800